New Fortress Energy
NFE
SilverCrest Metals
SILV
Hutchmed (China)
HCM
Dorian LPG
LPG
Precision Drilling
PDS
US Stock MarketDetailed Quotes
CALT Calliditas Therapeutics
- 40.000
- 0.0000.00%
Close Sep 20 16:00 ET
1.08BMarket Cap-24.91P/E (TTM)
0.000High0.000Low0Volume0.000Open40.000Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)27.02MShares43.00052wk High112.68P/B13.54MFloat Cap16.00052wk Low--Dividend TTM338.45KShs Float43.000Historical High--Div YieldTTM0.00%Amplitude10.820Historical Low--Avg Price1Lot Size
About Calliditas Therapeutics Company
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.
Company Profile
SymbolCALT
Company NameCalliditas Therapeutics
Issue Price19.50
CEOMs. Renee Aguiar-Lucander
MarketNASDAQ
Employees195
Securities TypeDR
ADS Ratio1.0 : 2.0
Fiscal Year Ends12-31
Company Executives
- Name
- Position
- Salary
- Renee Aguiar-Lucander
- Chief Executive Officer
- --
- Fredrik Johansson
- Chief Financial Officer
- --
- Dr. Richard Philipson, M.D.
- Chief Medical Officer
- --
- Dr. Frank Bringstrup, M.D.
- Vice President, Regulatory Affairs
- --
- Monika Maria Tornsen
- President, North America
- --
- Elmar Schnee
- Chairman of the Board
- --
- Henrik Stenqvist
- Independent Director
- --
- Dr. Elisabeth Bjork, M.D.,PhD
- Independent Director
- --
- Hilde Furberg
- Independent Director
- --
- Diane L. Parks, M.B.A.
- Independent Director
- --
- Frederick W. Driscoll
- Independent Director
- --
- Brian Gorman
- Group General Counsel
- --
- Lars Stubberud
- Head of Technical Operations
- --